×
About 605 results

ALLMedicine™ Pseudomonas Aeruginosa Infections Center

Research & Reviews  293 results

Failed eradication therapy of new onset Pseudomonas aeruginosa infections in cystic fib...
https://doi.org/10.1093/infdis/jiab102
The Journal of Infectious Diseases; Kwong K, Benedetti A et. al.

Feb 19th, 2021 - Antibiotics, such as inhaled tobramycin are used to eradicate new onset Pseudomonas aeruginosa (PA) infections in cystic fibrosis (CF) patients but frequently fail due to reasons poorly understood. We hypothesized that PA isolates' resistance to n...

Skin manifestations of Pseudomonas aeruginosa infections.
https://doi.org/10.1097/QCO.0000000000000717
Current Opinion in Infectious Diseases; Spernovasilis N, Psichogiou M et. al.

Jan 25th, 2021 - Pseudomonas aeruginosa is an opportunistic pathogen with considerable morbidity and mortality, particularly in vulnerable hosts. Skin manifestations are common, either representing local inoculation or secondary skin seeding following bloodstream ...

Outbreak of Pseudomonas aeruginosa Infections from a Contaminated Gastroscope Detected ...
https://doi.org/10.1093/cid/ciaa1887
Clinical Infectious Diseases : an Official Publication Of... Sundermann AJ, Chen J et. al.

Dec 28th, 2020 - Traditional methods of outbreak investigations utilize reactive whole genome sequencing (WGS) to confirm or refute the outbreak. We have implemented WGS surveillance and a machine learning (ML) algorithm for the electronic health record (EHR) to r...

Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa inf...
https://doi.org/10.1016/j.ijantimicag.2020.106270
International Journal of Antimicrobial Agents; Balandin B, Ballesteros D et. al.

Dec 21st, 2020 - This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients. A multicenter, retrospective and observational study was conducted in critica...

A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aerugi...
https://doi.org/10.1177/1060028020974003
The Annals of Pharmacotherapy; Blomquist KC, Nix DE

Nov 24th, 2020 - This article critically evaluates common Pseudomonas aeruginosa resistance mechanisms and the properties newer β-lactam antimicrobials possess to evade these mechanisms. An extensive PubMed, Google Scholar, and ClinicalTrials.gov search was conduc...

see more →

Guidelines  2 results

International Consensus Guidelines for the Optimal Use of the Polymyxins
https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2209

Feb 1st, 2019 - The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the 1950s and thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage thera...

Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinet...
http://www.who.int/infection-prevention/publications/guidelines-cre/en/
WHO

Oct 31st, 2017 - Health care-associated infections (HAI) are one of the most common adverse events in care delivery. A large proportion are caused by antibiotic resistant organisms.

see more →

Clinicaltrials.gov  303 results

Failed eradication therapy of new onset Pseudomonas aeruginosa infections in cystic fib...
https://doi.org/10.1093/infdis/jiab102
The Journal of Infectious Diseases; Kwong K, Benedetti A et. al.

Feb 19th, 2021 - Antibiotics, such as inhaled tobramycin are used to eradicate new onset Pseudomonas aeruginosa (PA) infections in cystic fibrosis (CF) patients but frequently fail due to reasons poorly understood. We hypothesized that PA isolates' resistance to n...

Skin manifestations of Pseudomonas aeruginosa infections.
https://doi.org/10.1097/QCO.0000000000000717
Current Opinion in Infectious Diseases; Spernovasilis N, Psichogiou M et. al.

Jan 25th, 2021 - Pseudomonas aeruginosa is an opportunistic pathogen with considerable morbidity and mortality, particularly in vulnerable hosts. Skin manifestations are common, either representing local inoculation or secondary skin seeding following bloodstream ...

Outbreak of Pseudomonas aeruginosa Infections from a Contaminated Gastroscope Detected ...
https://doi.org/10.1093/cid/ciaa1887
Clinical Infectious Diseases : an Official Publication Of... Sundermann AJ, Chen J et. al.

Dec 28th, 2020 - Traditional methods of outbreak investigations utilize reactive whole genome sequencing (WGS) to confirm or refute the outbreak. We have implemented WGS surveillance and a machine learning (ML) algorithm for the electronic health record (EHR) to r...

Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa inf...
https://doi.org/10.1016/j.ijantimicag.2020.106270
International Journal of Antimicrobial Agents; Balandin B, Ballesteros D et. al.

Dec 21st, 2020 - This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients. A multicenter, retrospective and observational study was conducted in critica...

A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aerugi...
https://doi.org/10.1177/1060028020974003
The Annals of Pharmacotherapy; Blomquist KC, Nix DE

Nov 24th, 2020 - This article critically evaluates common Pseudomonas aeruginosa resistance mechanisms and the properties newer β-lactam antimicrobials possess to evade these mechanisms. An extensive PubMed, Google Scholar, and ClinicalTrials.gov search was conduc...

see more →

News  7 results

Filamentous bacteriophage linked to lung infections in patients with cystic fibrosis
https://www.mdedge.com/internalmedicine/article/199114/pulmonology/filamentous-bacteriophage-linked-lung-infections?channel=27970
Steve Cimino

Apr 18th, 2019 - Filamentous bacteriophage (Pf phage) may contribute to Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients, according to a study of the prevalence and clinical relevance of Pf phage in two patient cohorts. CDC/ Janice Haney Carr A n.

International Consensus Guidelines for the Optimal Use of the Polymyxins
https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2209

Feb 1st, 2019 - The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the 1950s and thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage thera...

FDA Panel Gives High Sign for New CF Drug
https://www.medpagetoday.com/pulmonology/cysticfibrosis/34590

Sep 5th, 2012 - An FDA advisory committee voted 13-1 to recommend approval for a dry-powder formulation of tobramycin to treat pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients. Although agency staff had questioned the product's efficacy and...

Verona Integron-Encoded Metallo-β-Lactamase–Producing Carbapenem-Resistant Pseudomonas Aeruginosa Infections in U.S. Residents Associated With Invasive Medical Procedures in Mexico, 2015–2018
https://www.staging.medscape.com/viewarticle/913569

Verona integron-encoded metallo-β-lactamase–producing carbapenem-resistant Pseudomonas aeruginosa (VIM-CRPA) and other carbapenemase-producing organisms represent an emerging U.S. public health threat because of high levels of antibiotic resistanc...

The Pseudomonas aeruginosa Conundrum
https://www.medscape.com/viewarticle/744774

Abstract and Introduction Abstract The use of combination antibiotic therapy for severe pseudomonal infections is a standard practice in many hospitals; however, the data supporting its use are somewhat unclear. Possible benefits of combination th...

see more →